Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOSON: Sofosbuvir Regimens in Genotype 2/3 HCV
NCT01962441Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of sofosbuvir in hepatitis C (HCV) (4 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event up to 24 weeks. Started Sep 2013; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01962441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962441.